BridgeBio Pharma, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 27 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-07-09: Reporting owner Ellis Andrea; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-07-09: Reporting owner Cook Jennifer E.; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-07-09: Reporting owner Cook Jennifer E.; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-07-09: Reporting owner Cook Jennifer E.; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
BBIO insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | Ellis Andrea Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,167 17,167 owned after | $16.75 exercise price | $90.17 | 2026-07-13 |
| 2026-07-09 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −19,000 0 owned after | $8.45 exercise price | $90.17 | 2026-07-13 |
| 2026-07-09 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −112,422 0 owned after | $29.00 exercise price | $90.17 | 2026-07-13 |
| 2026-07-09 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,167 0 owned after | $16.75 exercise price | $90.17 | 2026-07-13 |
| 2026-06-24 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 19,000 owned after | $8.45 exercise price | $69.36 | 2026-06-24 |
| 2026-06-24 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,167 17,167 owned after | $16.75 exercise price | $69.36 | 2026-06-24 |
| 2026-06-22 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | Valantine Hannah Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | Valantine Hannah Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,808 5,617 owned after | $41.73 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | Lo Andrew Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | HOMCY CHARLES J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | AGUIAR ERIC Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | DANIELS RONALD J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | Ellis Andrea Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | Hassan Fred Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | MOMTAZEE JAMES C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | MCCORMICK FRANK Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | Dachille Douglas A. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-22 | Satvat Ali J. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,277 5,277 owned after | $68.92 exercise price | $68.92 | 2026-06-24 |
| 2026-06-15 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −65,921 39,000 owned after | $8.45 exercise price | $68.00 | 2026-06-17 |
| 2026-06-15 | Cook Jennifer E. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,167 34,334 owned after | $16.75 exercise price | $68.00 | 2026-06-17 |
| 2026-05-15 | Scott Randal W. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 21,501 owned after | $16.75 exercise price | $66.13 | 2026-05-19 |
| 2026-03-17 | Kumar Neil Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,570 40,570 owned after | $70.94 exercise price | $70.94 | 2026-03-19 |
| 2026-03-10 | Valantine Hannah Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,671 17,343 owned after | $27.36 exercise price | $74.32 | 2026-03-12 |
| 2026-03-04 | Ellis Andrea Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −64,921 0 owned after | $8.45 exercise price | $66.54 | 2026-03-06 |
| 2026-02-27 | Valantine Hannah Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,484 0 owned after | $48.45 exercise price | $66.48 | 2026-03-03 |
| 2026-02-17 | Scott Randal W. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 31,501 owned after | $16.75 exercise price | $75.85 | 2026-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |